Stephanie Monaghan O's most recent trade in Apellis Pharmaceuticals Inc was a trade of 5,750 Common Stock done . Disclosure was reported to the exchange on April 6, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Apellis Pharma Inc | Stephanie Monaghan O'Brien | Director | Other type of transaction at price $ 0.00 per share. | 06 Apr 2026 | 5,750 | 5,750 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharma Inc | Stephanie Monaghan O'Brien | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2026 | 14,684 | 14,684 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharma Inc | Stephanie Monaghan O'Brien | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2026 | 7,961 | 25,666 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharma Inc | Stephanie Monaghan O'Brien | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2025 | 11,199 | 11,199 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharma Inc | Stephanie Monaghan O'Brien | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2025 | 6,267 | 17,705 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharma Inc | O'Brien Monaghan Stephanie | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2024 | 5,748 | 5,748 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharma Inc | O'Brien Stephanie Monaghan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2024 | 3,341 | 11,438 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharma Inc | Stephanie Monaghan O'Brien | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2023 | 7,441 | 7,441 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharma Inc | Stephanie Monaghan O'Brien | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2023 | 3,867 | 8,097 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharma Inc | Stephanie Monaghan O'Brien | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2022 | 8,554 | 8,554 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharma Inc | Stephanie Monaghan O'Brien | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2022 | 4,230 | 4,230 (0%) | 0% | 0 | Common Stock |